Back آناكينرا Arabic آناکینرا AZB Anakinra Catalan Anakinra German Anakinra Spanish آناکینرا FA Anakinra French Anakinra ID Anakinra Italian Anakinra Dutch
 | |
| Clinical data | |
|---|---|
| Trade names | Kineret |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a602001 |
| License data | |
| Pregnancy category |
|
| Routes of administration | Subcutaneous |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 95% |
| Metabolism | predominantly kidney |
| Elimination half-life | 4-6 hrs |
| Identifiers | |
| |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C759H1186N208O232S10 |
| Molar mass | 17257.66 g·mol−1 |
  (what is this?) (verify) | |
Anakinra, sold under the brand name Kineret, is a biopharmaceutical medication used to treat rheumatoid arthritis, cryopyrin-associated periodic syndromes, familial Mediterranean fever, and Still's disease.[3] It is a slightly modified recombinant version of the human interleukin 1 receptor antagonist protein.[3] It is marketed by Swedish Orphan Biovitrum.[1] Anakinra is administered by subcutaneous injection.[2]
- ^ a b "Kineret 100 mg solution for injection in a pre-filled syringe - Summary of Product Characteristics (SmPC)". UK Electronic Medicines Compendium. Retrieved 2 March 2022.
- ^ a b Cite error: The named reference
Kineret FDA labelwas invoked but never defined (see the help page). - ^ a b c "Kineret EPAR". European Medicines Agency. 17 September 2018. Retrieved 20 July 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ "COVID-19 medicines". European Medicines Agency (EMA). 14 October 2024. Retrieved 14 October 2024.